MX2015000730A - Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. - Google Patents
Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.Info
- Publication number
- MX2015000730A MX2015000730A MX2015000730A MX2015000730A MX2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- her2 antibody
- antibody
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261673201P | 2012-07-18 | 2012-07-18 | |
US201261673229P | 2012-07-18 | 2012-07-18 | |
US201261673216P | 2012-07-18 | 2012-07-18 | |
EP12197768 | 2012-12-18 | ||
PCT/EP2013/065189 WO2014013019A1 (en) | 2012-07-18 | 2013-07-18 | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015000730A true MX2015000730A (es) | 2015-08-06 |
Family
ID=49948317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000730A MX2015000730A (es) | 2012-07-18 | 2013-07-18 | Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150166664A1 (zh) |
EP (1) | EP2874658A1 (zh) |
JP (1) | JP2015528802A (zh) |
KR (1) | KR20150036710A (zh) |
CN (1) | CN104394887A (zh) |
AU (1) | AU2013291964B2 (zh) |
BR (1) | BR112014032169A2 (zh) |
CA (1) | CA2875486A1 (zh) |
EA (1) | EA201590237A1 (zh) |
IL (1) | IL236714A0 (zh) |
MA (1) | MA37961A1 (zh) |
MX (1) | MX2015000730A (zh) |
NZ (1) | NZ701974A (zh) |
SG (1) | SG11201407841YA (zh) |
WO (1) | WO2014013019A1 (zh) |
ZA (1) | ZA201408938B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU92659B1 (en) * | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
CN111315776A (zh) * | 2017-03-29 | 2020-06-19 | 葛莱高托普有限公司 | Pd-l1和ta-muc1抗体 |
WO2019237322A1 (en) * | 2018-06-15 | 2019-12-19 | Shanghai Miracogen Inc | Methods and materials for treating cancer |
WO2022022526A1 (zh) * | 2020-07-28 | 2022-02-03 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
JP5425365B2 (ja) * | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 増加したFcレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用 |
FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
US7273608B2 (en) * | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
EA017622B1 (ru) * | 2006-09-10 | 2013-01-30 | Гликотоп Гмбх | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков |
RU2583298C2 (ru) * | 2009-10-07 | 2016-05-10 | Макродженикс, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
-
2013
- 2013-07-18 JP JP2015522098A patent/JP2015528802A/ja active Pending
- 2013-07-18 MA MA37961A patent/MA37961A1/fr unknown
- 2013-07-18 AU AU2013291964A patent/AU2013291964B2/en not_active Expired - Fee Related
- 2013-07-18 MX MX2015000730A patent/MX2015000730A/es unknown
- 2013-07-18 WO PCT/EP2013/065189 patent/WO2014013019A1/en active Application Filing
- 2013-07-18 BR BR112014032169A patent/BR112014032169A2/pt not_active IP Right Cessation
- 2013-07-18 KR KR20157004250A patent/KR20150036710A/ko not_active Application Discontinuation
- 2013-07-18 EA EA201590237A patent/EA201590237A1/ru unknown
- 2013-07-18 US US14/412,797 patent/US20150166664A1/en not_active Abandoned
- 2013-07-18 CA CA2875486A patent/CA2875486A1/en not_active Abandoned
- 2013-07-18 NZ NZ701974A patent/NZ701974A/en not_active IP Right Cessation
- 2013-07-18 EP EP13739973.9A patent/EP2874658A1/en not_active Withdrawn
- 2013-07-18 CN CN201380034959.0A patent/CN104394887A/zh active Pending
- 2013-07-18 SG SG11201407841YA patent/SG11201407841YA/en unknown
-
2014
- 2014-12-05 ZA ZA2014/08938A patent/ZA201408938B/en unknown
-
2015
- 2015-01-14 IL IL236714A patent/IL236714A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL236714A0 (en) | 2015-02-26 |
CA2875486A1 (en) | 2014-01-23 |
EP2874658A1 (en) | 2015-05-27 |
US20150166664A1 (en) | 2015-06-18 |
CN104394887A (zh) | 2015-03-04 |
SG11201407841YA (en) | 2015-02-27 |
AU2013291964A1 (en) | 2015-02-05 |
JP2015528802A (ja) | 2015-10-01 |
WO2014013019A1 (en) | 2014-01-23 |
KR20150036710A (ko) | 2015-04-07 |
AU2013291964B2 (en) | 2017-12-14 |
NZ701974A (en) | 2018-03-23 |
EA201590237A1 (ru) | 2015-05-29 |
BR112014032169A2 (pt) | 2017-08-01 |
ZA201408938B (en) | 2016-09-28 |
MA37961A1 (fr) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220162332A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
JP7046973B2 (ja) | 抗ox40抗体およびその使用 | |
RU2733315C2 (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
KR20140113912A (ko) | Her3에 특이적인 결합 분자 및 이의 용도 | |
US20160068609A1 (en) | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation | |
JP2017507953A (ja) | 抗cd38抗体との併用療法 | |
EP3067062A1 (en) | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament | |
CN115698068A (zh) | 抗tigit抗体 | |
US20210070862A1 (en) | B7-h4 antibody dosing regimens | |
CN114901306A (zh) | 用于治疗癌症的疗法 | |
WO2018182420A1 (en) | Antibodies for the treatment of erbb-2/erbb-3 positive tumors | |
AU2013291964B2 (en) | Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation | |
JP7065935B2 (ja) | 抗ly6g6d抗体及び使用方法 | |
JP2020533278A (ja) | K−Ras遺伝子の状態に関連したCK8陽性がんの治療 | |
WO2023227115A1 (en) | A method of treating solid tumor | |
JP2024515879A (ja) | 抗siglec組成物及びその使用 | |
TW202340243A (zh) | 抗cd39抗體及其用途 | |
Geuijen et al. | Application of unbiased combinatorial screening to generate a bispecific IgG1 that selectively and potently inhibits HER3 signaling via HER2-guided ligand blockade | |
CA3064588A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
WO2017102789A1 (en) | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |